Company: Aurobindo Pharma Ltd. Category: Broker Research

ARBP shines with a steady track record for resolving plant related issues and moving up the value chain with more number of approvals in complex drugs.
April 4, 2019, 11:53 a.m.

Aurobindo Pharmaceuticals (APL) has a big relief in form of Establishment Inspection report (EIR) for Unit-4 facility in which the USFDA has closed issued Form 483.
March 13, 2019, 11:26 a.m.

Aurobindo Pharma (ARBP) would acquire seven marketed oncology products, intellectual property and commercial infrastructure from Spectrum Pharma for a consideration of USD300m, which includes an upfront payment of USD160m and a milestone-linked payment of USD140m.
Jan. 17, 2019, 11:32 a.m.

We believe ARBP is likely to benefit from Pfizer’s rationalization of two injectable plants in India, which are key contributors in limited competition drugs, Tazo+Pip and Penems.
Jan. 10, 2019, 11:51 a.m.

Aurobindo Pharma’s (APL) acquisition of Sandoz’s product portfolio (dermatology and oral solids) for US$900mn will fetch a similar amount in incremental sales (30% from dermatology products and the rest from oral solids) in the first full year post transaction closure (six to nine months from the announcement).
Sept. 10, 2018, 11:20 a.m.

Aurobindo Pharmaceuticals (APL) has acquired dermatology and oral solids businesses from Sandoz Inc., USA for an upfront purchase price of US$0.9bn in cash.
Sept. 7, 2018, 10:46 a.m.

ARBP has acquired a selected group of products of Sandoz in derma, CNS, women healthcare and hormonal drugs in US.
Sept. 6, 2018, 10:47 a.m.

Aurobindo Pharma (ARBP) will acquire the dermatology and oral solids business(sales of USD0.6b in 1HCY18) from Sandoz for a cash consideration of USD900m(includes net working capital of USD220m).
Sept. 6, 2018, 10:46 a.m.

AuroMedics has voluntarily recalled two lots of injectable drug, combination of Piperacillin and Tazobactam (Tazo-Pip) of dosage strength of 3.375gm.
Aug. 1, 2018, 10:49 a.m.

Aurobindo Pharmaceuticals is an India-based leading global generic company. It’s predominately formulations export company, with USA & Europe contributing ~70% of sales (FY2018).
July 3, 2018, 11:46 a.m.